<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Indications for prophylactic implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapy in patients with inherited <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> stem from observational studies and are uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>This study evaluates the efficacy and harm rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantations for primary prevention compared with secondary prevention in inherited <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Between January 1, 1993, and April 1, 2011, 354 patients with inherited <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e> were treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Incidence rates of appropriate shocks in primary prevention patients with <z:hpo ids='HP_0011663'>arrhythmogenic right ventricular cardiomyopathy</z:hpo> and <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> were 4.2 to 6.7/100 patient-years, whereas the risk for appropriate shocks in primary prevention patients with <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e>, <z:hpo ids='HP_0001657'>long QT syndrome</z:hpo>, or carrying the DPP6 haplotype approached zero </plain></SENT>
<SENT sid="4" pm="."><plain>Conversely, in secondary prevention patients there was a considerably higher incidence rate of appropriate shocks </plain></SENT>
<SENT sid="5" pm="."><plain>None of the indications for primary prevention were associated with appropriate shock therapy </plain></SENT>
<SENT sid="6" pm="."><plain>One hundred twenty-three patients (35%) experienced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-related adverse events </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: For <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e>, <z:hpo ids='HP_0001657'>long QT syndrome</z:hpo>, and DPP6 the efficacy of an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> for primary prevention contrasts with the amount of harm, and factors that formed the indication for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation do not relate to the occurrence of appropriate shocks </plain></SENT>
<SENT sid="8" pm="."><plain>The higher appropriate discharge rates in <z:hpo ids='HP_0011663'>arrhythmogenic right ventricular cardiomyopathy</z:hpo> and <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> compared with primary electric diseases might result from a more advanced risk stratification scheme in these inherited <z:hpo ids='HP_0001638'>cardiomyopathies</z:hpo> </plain></SENT>
</text></document>